A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 45/06 (2006.01) A61K 31/404 (2006.01) A61K 31/517 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2683559
Provided herein are methods for treating cancer that is resistant to treatment with an anti- ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti- ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
L'invention concerne des méthodes pour traiter un cancer qui est résistant à un traitement au moyen d'un agent thérapeutique anti-ErbB et qui est associé à une mutation activante du gène MET ou une amplification du gène MET. Ces méthodes consistent notamment à administrer à un sujet une association d'un agent thérapeutique anti-ErbB et d'un agent thérapeutique anti-MET. L'invention concerne également des méthodes pour réduire la signalisation médiée par ErbB ou la signalisation médiée par la PI3-kinase dans une cellule cancéreuse.
Cantley Lewis C.
Engelman Jeffrey
Janne Pasi A.
Beth Israel Deaconess Medical Center Inc.
Borden Ladner Gervais Llp
Dana Farber Cancer Institute Inc.
The General Hospital Corporation D/b/a Massachusetts General Hos
LandOfFree
Methods for treating cancer resistant to erbb therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancer resistant to erbb therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancer resistant to erbb therapeutics will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1482691